Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy

71Citations
Citations of this article
136Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder. Main body: This review summarizes current knowledge of NY-ESO-1 as efficient biomarker and target of immunotherapy. It also addresses limitations and challenges preventing a robust immune response to NY-ESO-1 expressing cancers, and describes pre-clinical and clinical observations relevant to NY-ESO-1 immunity, holding potential therapeutic relevance for cancer treatment. Conclusion: NY-ESO-1 induces strong immune responses in cancer patients but has limited objective clinical responses to NY-ESO-1 expressing tumors due to effect of competitive negative signaling from immune-checkpoints and immune-suppressive tumor microenvironment. We propose that combination therapy to increase the efficacy of NY-ESO-1 specific immunotherapeutic interventions should be explored to unleash the immune response against NY-ESO-1 expressing tumors.

References Powered by Scopus

Myeloid-derived suppressor cells as regulators of the immune system

5573Citations
N/AReaders
Get full text

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

4388Citations
N/AReaders
Get full text

The immunobiology of cancer immunosurveillance and immunoediting

2363Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities

213Citations
N/AReaders
Get full text

Advances and challenges in the treatment of esophageal cancer

138Citations
N/AReaders
Get full text

TCR recognition of peptide–MHC-I: Rule makers and breakers

95Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Raza, A., Merhi, M., Inchakalody, V. P., Krishnankutty, R., Relecom, A., Uddin, S., & Dermime, S. (2020, March 27). Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. Journal of Translational Medicine. BioMed Central Ltd. https://doi.org/10.1186/s12967-020-02306-y

Readers over time

‘20‘21‘22‘23‘24010203040

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 44

57%

Researcher 28

36%

Professor / Associate Prof. 5

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 22

35%

Medicine and Dentistry 16

26%

Agricultural and Biological Sciences 12

19%

Immunology and Microbiology 12

19%

Article Metrics

Tooltip
Mentions
News Mentions: 68
Social Media
Shares, Likes & Comments: 30

Save time finding and organizing research with Mendeley

Sign up for free
0